{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:22:33Z","timestamp":1792027353679,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>High-dose daptomycin is increasingly used in patients with bone and joint infection (BJI). This raises concerns about a higher risk of adverse events (AEs), including daptomycin-induced eosinophilic pneumonia (DIEP) and myotoxicity. We aimed to examine pharmacokinetic and other potential determinants of DIEP and myotoxicity in patients with BJI receiving daptomycin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All patients receiving daptomycin for BJI were identified in a prospective cohort study. Cases were matched at a 1:3 ratio, with controls randomly selected from the same cohort. Bayesian estimation of the daptomycin daily area under the concentration-time curve over 24 hours (AUC24h) was performed with the Monolix software based on therapeutic drug monitoring (TDM) data. Demographic and biological data were also collected. Risk factors of AEs were analyzed using Cox proportional hazards model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 1130 patients followed over 7 years, 9 with DIEP, 26 with myotoxicity, and 106 controls were included in the final analysis. Daptomycin AUC24h, C-reactive protein, and serum protein levels were associated with the risk of AEs. The adjusted hazard ratio of DIEP or myotoxicity was 3.1 (95% confidence interval [CI], 1.48\u20136.5; P &amp;lt; .001) for daptomycin AUC24h &amp;gt; 939 mg\/h\/L, 9.8 (95% CI, 3.94\u201324.5; P &amp;lt; .001) for C-reactive protein &amp;gt; 21.6 mg\/L, and 2.4 (95% CI, 1.02\u20135.65; P = .04) for serum protein &amp;lt;72 g\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We identified common determinants of DIEP and myotoxicity in patients with BJI. Because the risk of AEs was associated with daptomycin exposure, daptomycin TDM and model-informed precision dosing may help optimize the efficacy and safety of daptomycin treatment in this setting. A target AUC24h range of 666 to 939 mg\/h\/L is suggested.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad386","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T23:49:23Z","timestamp":1689810563000},"page":"1372-1380","source":"Crossref","is-referenced-by-count":33,"title":["Daptomycin Exposure as a Risk Factor for Daptomycin-Induced Eosinophilic Pneumonia and Muscular Toxicity"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-4808","authenticated-orcid":false,"given":"Romain","family":"Garreau","sequence":"first","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie , Lyon , France"},{"name":"LBBE\u2014Laboratoire de Biom\u00e9trie et Biologie Evolutive, CNRS, UMR 5558, Universit\u00e9 Lyon 1 , Villeurbanne , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0284-7080","authenticated-orcid":false,"given":"Truong-Thanh","family":"Pham","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Geneva University Hospitals , Geneva , Switzerland"},{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, H\u00f4pital de la Croix-Rousse, Service des Maladies Infectieuses et Tropicales, Centre de R\u00e9f\u00e9rence pour la prise en charge des Infections Ost\u00e9o-Articulaires complexes (CRIOAc Lyon) , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bourguignon","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie , Lyon , France"},{"name":"LBBE\u2014Laboratoire de Biom\u00e9trie et Biologie Evolutive, CNRS, UMR 5558, Universit\u00e9 Lyon 1 , Villeurbanne , France"},{"name":"Facult\u00e9s de M\u00e9decine et de Pharmacie de Lyon, Univ Lyon, Universit\u00e9 Lyon 1, ISPB , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Millet","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Service de Biochimie et Biologie Mol\u00e9culaire, UM Pharmacologie -Toxicologie , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Parant","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Sud, Service de Biochimie et Biologie Mol\u00e9culaire, UM Pharmacologie -Toxicologie , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bussy","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, H\u00f4pital de la Croix-Rousse, Service des Maladies Infectieuses et Tropicales, Centre de R\u00e9f\u00e9rence pour la prise en charge des Infections Ost\u00e9o-Articulaires complexes (CRIOAc Lyon) , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Desevre","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, H\u00f4pital de la Croix-Rousse, Service des Maladies Infectieuses et Tropicales, Centre de R\u00e9f\u00e9rence pour la prise en charge des Infections Ost\u00e9o-Articulaires complexes (CRIOAc Lyon) , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Franchi","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, H\u00f4pital de la Croix-Rousse, Service des Maladies Infectieuses et Tropicales, Centre de R\u00e9f\u00e9rence pour la prise en charge des Infections Ost\u00e9o-Articulaires complexes (CRIOAc Lyon) , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, H\u00f4pital de la Croix-Rousse, Service des Maladies Infectieuses et Tropicales, Centre de R\u00e9f\u00e9rence pour la prise en charge des Infections Ost\u00e9o-Articulaires complexes (CRIOAc Lyon) , Lyon , France"},{"name":"Facult\u00e9s de M\u00e9decine et de Pharmacie de Lyon, Univ Lyon, Universit\u00e9 Lyon 1, ISPB , Lyon , France"},{"name":"CIRI\u2014Centre International de Recherche en Infectiologie, Inserm, U1111, Universit\u00e9\u0301 Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Sup\u00e9rieure de Lyon, Univ Lyon , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-2932","authenticated-orcid":false,"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Groupement Hospitalier Nord, Service de Pharmacie , Lyon , France"},{"name":"LBBE\u2014Laboratoire de Biom\u00e9trie et Biologie Evolutive, CNRS, UMR 5558, Universit\u00e9 Lyon 1 , Villeurbanne , France"},{"name":"Facult\u00e9s de M\u00e9decine et de Pharmacie de Lyon, Univ Lyon, Universit\u00e9 Lyon 1, ISPB , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"2023111710162994500_ciad386-B1","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1128\/AAC.00038-12","article-title":"Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty","volume":"56","author":"Byren","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023111710162994500_ciad386-B2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12879-016-1420-7","article-title":"Daptomycin &gt; 6 mg\/kg\/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center","volume":"16","author":"Roux","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2023111710162994500_ciad386-B3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1471-2334-12-133","article-title":"Daptomycin therapy for osteomyelitis: a retrospective study","volume":"12","author":"Gallagher","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2023111710162994500_ciad386-B4","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.amjmed.2007.07.010","article-title":"Clinical experience with daptomycin for the treatment of patients with osteomyelitis","volume":"120","author":"Lamp","year":"2007","journal-title":"Am J Med"},{"key":"2023111710162994500_ciad386-B5","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1128\/AAC.02597-15","article-title":"Pharmacokinetic variability of daptomycin during prolonged therapy for bone and joint infections","volume":"60","author":"Goutelle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023111710162994500_ciad386-B6","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dky541","article-title":"Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection","volume":"74","author":"Bricca","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023111710162994500_ciad386-B7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/jac\/dkab006","article-title":"Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference","volume":"76","author":"Garreau","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023111710162994500_ciad386-B8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/1060028021991943","article-title":"High-dose daptomycin and clinical applications","volume":"55","author":"Jones","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2023111710162994500_ciad386-B9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ajhp\/zxy036","article-title":"Musculoskeletal toxicities in patients receiving concomitant statin and daptomycin therapy","volume":"76","author":"Kido","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"2023111710162994500_ciad386-B10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40121-014-0041-y","article-title":"Effect of concomitant 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor therapy on creatine phosphokinase levels and mortality among patients receiving daptomycin: retrospective cohort study","volume":"3","author":"McConnell","year":"2014","journal-title":"Infect Dis Ther"},{"key":"2023111710162994500_ciad386-B11","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023111710162994500_ciad386-B12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz444","article-title":"A retrospective multisite case-control series of concomitant use of daptomycin and statins and the effect on creatine phosphokinase","volume":"6","author":"Lehman","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023111710162994500_ciad386-B13","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s10096-011-1500-y","article-title":"Safety analysis of high dose (&gt;6 mg\/kg\/day) daptomycin in patients with concomitant statin therapy","volume":"31","author":"Parra-Ruiz","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023111710162994500_ciad386-B14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13756-016-0158-8","article-title":"Daptomycin-induced eosinophilic pneumonia\u2014a systematic review","volume":"5","author":"Uppal","year":"2016","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023111710162994500_ciad386-B15","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab568","article-title":"Identification of risk factors for daptomycin-associated creatine phosphokinase elevation and development of a risk prediction model for incidence probability","volume":"8","author":"Samura","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023111710162994500_ciad386-B16","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac577","article-title":"Seventeen cases of daptomycin-induced eosinophilic pneumonia in a cohort of patients treated for bone and joint infections: proposal for a new algorithm","volume":"9","author":"Pham","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023111710162994500_ciad386-B17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2023111710162994500_ciad386-B18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/data7020016","article-title":"Regression-based approach to test missing data mechanisms","volume":"7","author":"Rouzinov","year":"2022","journal-title":"Data"},{"key":"2023111710162994500_ciad386-B19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1080\/01621459.1988.10478722","article-title":"A test of missing completely at random for multivariate data with missing values","volume":"83","author":"Little","year":"1988","journal-title":"J Am Stat Assoc"},{"key":"2023111710162994500_ciad386-B20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Stat Data Anal"},{"key":"2023111710162994500_ciad386-B21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/antibiotics10040446","article-title":"Risk factors of daptomycin-induced eosinophilic pneumonia in a population with osteoarticular infection","volume":"10","author":"Soldevila-Boixader","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2023111710162994500_ciad386-B22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jiac.2016.09.001","article-title":"Eosinophilic pneumonia caused by daptomycin: six cases from two institutions and a review of the literature","volume":"23","author":"Hirai","year":"2017","journal-title":"J Infect Chemother"},{"key":"2023111710162994500_ciad386-B23","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"2023111710162994500_ciad386-B24","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jinf.2006.11.006","article-title":"Eosinophilic pneumonia induced by daptomycin","volume":"54","author":"Hayes","year":"2007","journal-title":"J Infect"},{"key":"2023111710162994500_ciad386-B25","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1248\/bpb.b20-00217","article-title":"Evaluation of daptomycin-induced cellular membrane injury in skeletal muscle","volume":"43","author":"Yamada","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"2023111710162994500_ciad386-B26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMra0910283","article-title":"Hypoxia and inflammation","volume":"364","author":"Eltzschig","year":"2011","journal-title":"N Engl J Med"},{"key":"2023111710162994500_ciad386-B27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"J Infect Chemother"},{"key":"2023111710162994500_ciad386-B28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2023111710162994500_ciad386-B29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023111710162994500_ciad386-B30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/pharmaceutics14010114","article-title":"Implementation and comparison of two pharmacometric tools for model-based therapeutic drug monitoring and precision dosing of daptomycin","volume":"14","author":"Heitzmann","year":"2022","journal-title":"Pharmaceutics"},{"key":"2023111710162994500_ciad386-B31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2023111710162994500_ciad386-B32","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/cid\/ciy287","article-title":"Effect of statin coadministration on the risk of daptomycin-associated myopathy","volume":"67","author":"Dare","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023111710162994500_ciad386-B33","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/AAC.02910-14","article-title":"Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors","volume":"58","author":"Bland","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad386\/50913489\/ciad386.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/10\/1372\/53479296\/ciad386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/10\/1372\/53479296\/ciad386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T13:31:08Z","timestamp":1700227868000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/10\/1372\/7226491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,7,19]]},"published-print":{"date-parts":[[2023,11,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad386","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,15]]},"published":{"date-parts":[[2023,7,19]]}}}